LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment
Key Highlights
- ➤LB Pharmaceuticals will host R&D Day on October 27, 2026
- ➤Phase 3 schizophrenia topline readout expected in first half of 2027
- ➤NOVA-2 Phase 3 trial and ILLUMINATE-1 Phase 2 trial remain ongoing
- ➤LB-102 showed statistically significant benefit versus placebo at all Phase 2 doses
- ➤LB-102 demonstrated rapid week-one onset and sustained four-week benefit
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that it will host an in-person and virtual R&D Day on Tuesday, October 27, 2026, with presentations beginning at 2:00 PM ET and a reception to follow. The event will feature Roger S. McIntyre, MD, FRCPC (University of Toronto), alongside LB management team members Heather Turner (CEO), Susan G. Kozauer (CMO), Kaya Pai Panandiker (CCO), Gad Soffer (COBO), and Joe Miller (CFO), as the Company looks ahead to its upcoming topline Phase 3 data readout in schizophrenia. To register, click here.
LB-102 is a novel, investigational, once-daily oral selective antagonist of D2, D3 and 5HT7 receptors with a unique bimodal mechanism. It is being developed by LB Pharma for the treatment of schizophrenia, bipolar depression, the adjunctive treatment of major depressive disorder, as well as other neuropsychiatric disorders, and has the potential to be the first therapy with this unique mechanism approved for neuropsychiatric disorders in the United States.
Get started
Create a free account to read the full story.